Dissolution and dissolution/permeation experiments for predicting systemic exposure following oral administration of the BCS class II drug clarithromycin

European Journal of Pharmaceutical Sciences

Volumn 101, Issue , 2017, Pages 211-219

  Kristin, Forner ^a   René, Holm ^b   Boontida, Morakul ^c   Buraphacheep, Junyaprasert Varaporn ^c   Maximilian, Ackermann ^d   Johanna, Mazur ^d   Peter, Langguth ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Caco 2 cells; Excised rat intestinal sheets; Nanoparticles; Poloxamer 407; SLS; Ussing Chamber

Indexed keywords

CLARITHROMYCIN; DODECYL SULFATE SODIUM; EXCIPIENT; POLOXAMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CACO-2 CELL LINE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG SOLUBILITY; EX VIVO STUDY; FREEZE DRYING; IN VIVO STUDY; INTESTINE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; PRECIPITATION; PRIORITY JOURNAL; RAT; ANIMAL; CELL MEMBRANE PERMEABILITY; CHEMISTRY; DRUG EFFECTS; HUMAN; INTESTINE ABSORPTION; MEDICINAL CHEMISTRY; METABOLISM; MUCUS; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; PROCEDURES; SOLUBILITY; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CHEMISTRY, PHARMACEUTICAL; CLARITHROMYCIN; EXCIPIENTS; HUMANS; INTESTINAL ABSORPTION; INTESTINES; MALE; MUCUS; RATS; RATS, WISTAR; SOLUBILITY;

EID: 85013435828     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2017.02.003     Document Type: Article

References (42)

1. Artursson, P., Ungell, A., Löfroth, J., Selective paracellular permeability in two models of intestinal absorption: cultured monolayers of human intestinal epithelial cells and rat intestinal segments. Pharm. Res. 8 (1993), 1123–1129.
2. Berthelsen, R., Holm, R., Jacobsen, J., Kristensen, J., Abrahamsson, B., Müllertz, A., Dissolution model development: formulation effects and filter complications. Dissolut. Technol. 01 (2016), 6–12.
3. Boisset, M., Botham, R.P., Haegele, K.D., Lenfant, B., Pachot, J.I., Absorption of angiotensin II antagonists in Ussing chambers, Caco-2, perfused jejunum loop and in vivo. Eur. J. Pharm. Sci. 3 (2000), 215–224.
4. Boulenc, X., Breul, T., Gautier, J.-C., Saudemon, P., Joyeux, H., Roques, C., et al. Sodium lauryl sulphate increases tiludronate paracellular transport using human epithelial Caco-2 monolayers. Int. J. Pharm. 1 (1995), 71–83.
5. Buch, P., Langguth, P., Kataoka, M., Yamashita, S., IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system. J. Pharm. Sci. 6 (2009), 2001–2009.
6. Butler, J.M., Dressman, J.B., The developability classification system: application of biopharmaceutics concepts to formulation development. J. Pharm. Sci. 12 (2010), 4940–4954.
7. Cespi, M., Bonacucina, G., Pucciarelli, S., Cocci, P., Perinelli, D.R., Casettari, L., et al. Evaluation of thermosensitive poloxamer 407 gel systems for the sustained release of estradiol in a fish model. Eur. J. Pharm. Biopharm. 3 (2014), 954–961.
8. Costa, P., Sousa Lobo, J.M., Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 2 (2001), 123–133.
9. Desai, M.P., Labhasetwar, V., Walter, E., Levy, R.J., Amidon, G.L., The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm. Res. 11 (1997), 1568–1573.
10. Eloy, J.O., Saraiva, J., Albuquerque, S.d., Marchetti, J.M., Preparation, characterization and evaluation of the in vivo trypanocidal activity of ursolic acid-loaded solid dispersion with poloxamer 407 and sodium caprate. Braz. J. Pharm. Sci. 1 (2015), 101–109.
11. Galia, E., Nicolaides, E., Hörter, D., Löbenberg, R., Reppas, C., Dressman, J.B., Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 5 (1998), 698–705.
12. Gotoh, Y., The advantages of the Ussing chamber in drug absorption studies. J. Biomol. Screen. 5 (2005), 517–523.
13. Ha, E.-S., Choo, G.-H., Baek, I.-H., Kim, J.-S., Cho, W., Jung, Y.S., et al. Dissolution and bioavailability of lercanidipine–hydroxypropylmethyl cellulose nanoparticles with surfactant. Int. J. Biol. Macromol., 2015, 218–222.
14. Heinen, C., Einfluss von Hilfsstoffen auf die Bioverfügbarkeit von Substanzen der BCS Klasse III. Dissertation, 2013, Johannes Gutenberg-University, Mainz, 141.
15. Heinen, C., Reuss, S., Saaler-Reinhardt, S., Langguth, P., Mechanistic basis for unexpected bioavailability enhancement of polyelectrolyte complexes incorporating BCS class III drugs and carrageenans. Eur. J. Pharm. Biopharm. 1 (2013), 26–33.
16. Kataoka, M., Masaoka, Y., Yamazaki, Y., Sakane, T., Sezaki, H., Yamashita, S., In vitro system to evaluate oral absorption of poorly water-soluble drugs: simultaneous analysis on dissolution and permeation of drugs. Pharm. Res. 10 (2003), 1674–1680.
17. Kataoka, M., Masaoka, Y., Sakuma, S., Yamashita, S., Effect of food intake on the oral absorption of poorly water-soluble drugs: in vitro assessment of drug dissolution and permeation assay system. J. Pharm. Sci. 9 (2006), 2051–2061.
18. Kataoka, M., Sugano, K., da Costa Mathews, C., Wong, J.W., Jones, K.L., Masaoka, Y., et al. Application of dissolution/permeation system for evaluation of formulation effect on oral absorption of poorly water-soluble drugs in drug development. Pharm. Res. 6 (2012), 1485–1494.
19. Khoshakhlagh, P., Johnson, R., Nawroth, T., Langguth, P., Schmueser, L., Hellmann, N., et al. Nanoparticle structure development in the gastro-intestinal model fluid FaSSIF mod6.5 from several phospholipids at various water content relevant for oral drug administration. Eur. J. Lipid Sci. Technol. 9 (2014), 1155–1166.
20. Kovačević, I., Parojčić, J., Homšek, I., Tubić-Grozdanis, M., Langguth, P., Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation. Mol. Pharm. 1 (2009), 40–47.
21. Ku, M.S., Dulin, W., A biopharmaceutical classification-based Right-First-Time formulation approach to reduce human pharmacokinetic variability and project cycle time from First-In-Human to clinical Proof-Of-Concept. Pharm. Dev. Technol. 3 (2012), 285–302.
22. Lai, S.K., Wang, Y.-Y., Hanes, J., Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 2 (2009), 158–171.
23. Larhed, A.W., Artursson, P., Gråsjö, J., Björk, E., Diffusion of drugs in native and purified gastrointestinal mucus. J. Pharm. Sci. 6 (1997), 660–665.
24. Lennernäs, H., Human intestinal permeability. J. Pharm. Sci. 4 (1998), 403–410.
25. Martin, G.P., Marriott, C., Kellaway, I.W., Direct effect of bile salts and phospholipids on the physical properties of mucus. Gut 2 (1978), 103–107.
26. Menon, R., Barr, W., Comparison of ceftibuten transport across Caco-2 cells and rat jejunum mounted on modified Ussing chambers. Biopharm. Drug Dispos. 7 (2003), 299–308.
27. Morakul, B., Suksiriworapong, J., Leanpolchareanchai, J., Junyaprasert, V.B., Precipitation-lyophilization-homogenization (PLH) for preparation of clarithromycin nanocrystals: influencing factors on physicochemical properties and stability. Int. J. Pharm. 1 (2013), 187–196.
28. Morakul, B., Suksiriworapong, J., Chomnawang, M.T., Langguth, P., Junyaprasert, V.B., Dissolution enhancement and in vitro performance of clarithromycin nanocrystals produced by precipitation–lyophilization–homogenization method. Eur. J. Pharm. Biopharm. 3 (2014), 886–896.
29. Nicolaides, E., Galia, E., Efthymiopoulos, C., Dressman, J.B., Reppas, C., Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharm. Res. 12 (1999), 1876–1882.
30. Pillay, V., Fassihi, R., Evaluation and comparison of dissolution data derived from different modified release dosage forms: an alternative method. J. Control. Release 1 (1998), 45–55.
31. Reis, J., Dezani, A., Pereira, T., Avdeef, A., Serra, C., Lamivudine permeability study: a comparison between PAMPA, ex vivo and in situ Single-Pass Intestinal Perfusion (SPIP) in rat jejunum. Eur. J. Pharm. Sci. 4-5 (2013), 781–789.
32. Schamp, K., Schredder, S., Dressman, J.B., Development of an in vitro/in vivo correlation for lipid formulations of EMD 50733, a poorly soluble, lipophilic drug substance. Eur. J. Pharm. Biopharm. 3 (2006), 227–234.
33. Shah, V.P., Tsong, Y., Sathe, P., Liu, J., In vitro dissolution profile comparison — statistics and analysis of the similarity factor, f2. Pharm. Res. 6 (1998), 889–896.
34. Sironi, D., Rosenberg, J., Bauer-Brandl, A., Brandl, M., Dynamic dissolution-/permeation-testing of nano- and microparticle formulations of fenofibrate. Eur. J. Pharm. Sci., 2017, 20–27.
35. Skolnik, S., Lin, X., Wang, J., Chen, X.-H., He, T., Zhang, B., Towards prediction of in vivo intestinal absorption using a 96-well Caco-2 assay. J. Pharm. Sci. 7 (2010), 3246–3265.
36. Sunesen, V.H., Pedersen, B.L., Kristensen, H.G., Müllertz, A., In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media. Eur. J. Pharm. Sci. 4 (2005), 305–313.
37. Takano, R., Sugano, K., Higashida, A., Hayashi, Y., Machida, M., Aso, Y., Yamashita, S., Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm. Res. 6 (2006), 1144–1156.
38. Thomas, S., Brightman, F., Gill, H., Lee, S., Pufong, B., Simulation modelling of human intestinal absorption using Caco-2 permeability and kinetic solubility data for early drug discovery. J. Pharm. Sci. 10 (2008), 4557–4574.
39. Ungell, A.-L., Transport studies using intestinal tissue ex vivo. Lehr, Claus-Michael, (eds.) Cell Culture Models of Biological Barriers, 2002, CRC Press, 164–188.
40. Watanabe, E., Takahashi, M., Hayashi, M., A possibility to predict the absorbability of poorly water-soluble drugs in humans based on rat intestinal permeability assessed by an in vitro chamber method. Eur. J. Pharm. Biopharm. 3 (2004), 659–665.
41. Yamashita, S., Tanaka, Y., Endoh, Y., Taki, Y., Sakane, Y., Nadai, T., Sezaki, H., Analysis of drug permeation across Caco-2 monolayer: implication for predicting in vivo drug absorption. Pharm. Res. 14:4 (1997), 486–491.
42. Zhang, Y., Huo, M., Zhou, J., Xie, S., PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput. Methods Prog. Biomed. 3 (2010), 306–314.